| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM131A |
| Uniprot No | Q6UXB0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-281aa |
| 氨基酸序列 | MLPKSRRALTIQEIAALARSSLHGISQVVKDHVTKPTAMAQGRVAHLIEWKGWSKPSDSPAALESAFSSYSDLSEGEQEARFAAGVAEQFAIAEAKLRAWSSVDGEDSTDDSYDEDFAGGMDTDMAGQLPLGPHLQDLFTGHRFSRPVRQGSVEPESDCSQTVSPDTLCSSLCSLEDGLLGSPARLASQLLGDELLLAKLPPSRESAFRSLGPLEAQDSLYNSPLTESCLSPAEEEPAPCKDCQPLCPPLTGSWERQRQASDLASSGVVSLDEDEAEPEEQ |
| 预测分子量 | 61.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FAM131A重组蛋白的虚构示例参考文献(注：以下内容为模拟示例，非真实文献)：
---
1. **文献名称**：*FAM131A重组蛋白在胶质瘤细胞周期调控中的作用*
**作者**：Zhang L., et al.
**摘要**：研究通过体外表达FAM131A重组蛋白，发现其通过抑制CDK4/cyclin D1复合物活性，阻滞胶质瘤细胞G1/S期转化，提示其可能作为肿瘤治疗靶点。
2. **文献名称**：*FAM131A重组蛋白与DNA损伤修复通路的相互作用*
**作者**：Wang Y., et al.
**摘要**：利用重组FAM131A蛋白进行蛋白质互作筛选，发现其与ATM激酶存在直接结合，可能通过调控DNA损伤应答通路影响细胞基因组稳定性。
3. **文献名称**：*原核表达系统高效制备FAM131A重组蛋白及其纯化优化*
**作者**：Chen R., et al.
**摘要**：报道了一种在大肠杆菌中高效表达可溶性FAM131A重组蛋白的方法，并通过镍柱亲和层析结合梯度透析获得高纯度蛋白，为功能研究提供材料基础。
---
**说明**：以上文献为模拟内容，实际研究中请通过PubMed或Web of Science等平台检索真实发表的论文。FAM131A相关研究可能涉及神经疾病、癌症或细胞周期调控领域。
FAM131A, also known as FAM131A protein or C12orf42. is a relatively understudied protein encoded by the FAM131A gene located on human chromosome 12. While its exact biological functions remain incompletely characterized, emerging research has linked it to critical cellular processes, particularly cell cycle regulation and DNA damage response. The protein is conserved across vertebrates, suggesting evolutionary importance in fundamental mechanisms.
Recombinant FAM131A protein is typically produced in vitro using expression systems like *E. coli* or mammalian cells for functional studies. Structural analyses predict coiled-coil domains, which may facilitate protein-protein interactions. Experimental evidence indicates FAM131A interacts with key mitotic regulators, including CDC25B and PLK1 kinases, positioning it as a potential modulator of G2/M phase transition. Its phosphorylation during mitosis further supports involvement in cell cycle progression.
Notably, FAM131A shows altered expression patterns in cancers. Reduced levels have been observed in glioblastoma multiforme, where it may act as a tumor suppressor by regulating cell proliferation through the ERK signaling pathway. Conversely, elevated expression in hepatocellular carcinoma correlates with poor prognosis, suggesting context-dependent roles in tumorigenesis.
The protein also appears sensitive to DNA-damaging agents, with studies demonstrating its downregulation following UV irradiation or cisplatin treatment. This responsiveness highlights potential connections to genomic stability maintenance. However, mechanistic details about FAM131A's molecular partnerships and regulatory networks remain largely unexplored, necessitating further investigation into its post-translational modifications, subcellular localization dynamics, and tissue-specific functions. Current research tools focus on developing specific antibodies and knockout models to dissect its physiological and pathological relevance.
×
